Misarpy

Retail price

0.0

元

Market price

0.0

元

Number of views:

1000

Product serial number

Category

Other Therapeutic Agents

Quantity

Stock:



Large animal products：along@easternalong.com Small pet products：ca@easternalong.com

Back to list Contact Us

产品描述

Parameters

Description

1 ml contains:

Telmisartan 4 mg

Pharmaceutical Form

Oral solution.

Clear, colourless to yellowish viscous solution.

Indications

Angiotensin II receptor antagonist.

Cats: Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.

Treatment of systemic hypertension in cats .

Dosage and Administration

For oral use

The product is to be administered once daily directly into the mouth or with a small amount of food.

CKD – amounts to be administered once daily:
The recommended dose is 1 mg telmisartan/kg body weight.

Dosing: 1 mg telmisartan/kg body weight
Strength [mg/ml]	Dosage/kg body weight [ml]
4	0.25

Systemic hypertension – amounts to be administered once daily:
The initial recommended dose is 2 mg telmisartan/kg body weight.

Dosing: 2 mg telmisartan/kg body weight
Strength [mg/ml]	Dosage/kg body weight [ml]
4	0.5

After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinarian.
If the SBP increases over the course of the disease the daily dose may be increased again up to 2 mg/kg.
The target SBP range is between 120 and 140 mmHg. If SBP is below the target or if there are concurrent signs of hypotension, symptomatic treatment, e.g. fluid therapy, should be provided and the dosage of telmisartan should be reduced.

Systemic hypertension associated with CKD – amounts to be administered once daily:
The dosing regimen for hypertensive cats with concomitant chronic kidney disease is as described above for systemic hypertension except that for these cats the recommended minimum effective dose is 1 mg/kg.

Pharmacodynamic properties

Telmisartan is an orally active and specific angiotensin II receptor (subtype AT₁) antagonist which causes a dose-dependent decrease in mean arterial blood pressure in mammalian species, including the cat. In a clinical trial in cats with chronic kidney disease, a reduction in proteinuria was seen within the first 7 days after the start of treatment with 1 mg/kg. In a further clinical trial in cats with hypertension a reduction in mean systolic blood pressure was achieved with a dose of 2 mg/kg. Due to the combination of these pharmacodynamic properties, telmisartan is an appropriate treatment for cats with concomitant hypertension and CKD.

Telmisartan displaces angiotensin II from its binding site at the AT₁ receptor subtype. Telmisartan selectively binds to the AT₁ receptor and does not show affinity for other receptors, including AT₂ or other less characterised AT
receptors. Stimulation of the AT₁ receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis and organ remodelling. Effects associated with stimulation of the AT₂ receptor such as vasodilatation, natriuresis and inhibition of inappropriate cell growth are not suppressed. The receptor binding is long lasting due to the slow dissociation of telmisartan from the AT₁ receptor binding site. Telmisartan does not exhibit any partial agonist activity at the AT₁ receptor.